PT - JOURNAL ARTICLE AU - Richard J. Webster AU - Deepti Reddy AU - Mary-Ann Harrison AU - Ken J. Farion AU - Jacqueline Wilmore AU - Michelle Foote AU - Nisha Thampi TI - Predicting SARS-CoV-2 infections for children and youth with single symptom screening AID - 10.1101/2021.08.19.21262310 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.19.21262310 4099 - http://medrxiv.org/content/early/2021/08/23/2021.08.19.21262310.short 4100 - http://medrxiv.org/content/early/2021/08/23/2021.08.19.21262310.full AB - Symptom-based SARS-CoV-2 screening and testing decisions in children have important implications on daycare and school exclusion policies. Single symptoms account for a substantial volume of testing and disruption to in-person learning and childcare, yet their predictive value is unclear, given the clinical overlap with other circulating respiratory viruses and non-infectious etiologies. We aimed to determine the relative frequency and predictive value of single symptoms for paediatric SARS-CoV-2 infections from an Ottawa COVID-19 assessment centre from October 2020 through April 2021.Overall, 46.3% (n=10,688) of pediatric encounters were for single symptoms, and 2.7% of these tested positive. The most common presenting single symptoms were rhinorrhea (31.8%), cough (17.4%) and fever (14.0%). Among children with high-risk exposures children in each age group, the following single symptoms had a higher proportion of positive SARS-CoV-2 cases compared to no symptoms; fever and fatigue (0-4 years); fever, cough, headache, and rhinorrhea (5-12 years); fever, loss of taste or smell, headache, rhinorrhea, sore throat, and cough (13-17 years). There was no evidence that the single symptom of either rhinorrhea or cough predicted SARS-CoV-2 infections among 0-4 year olds, despite accounting for a large volume (61.1%) of single symptom presentations in the absence of high-risk exposures.Symptom-based screening needs to be responsive to changes in evidence and local factors, including the expected resurgence of other respiratory viruses following relaxation of social distancing/masking, to reduce infection-related risks in schools and daycare settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received The authors did not receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHEO Research Ethics Board approved this secondary use of health administrative dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request(SARS-CoV-2)Severe acute respiratory syndrome coronavirus 2(COVID-19)Coronavirus disease 2019(HRE)High-Risk Exposures(PPV)Positive Predictive Value(LR)Likelihood Ratio(NNT)Number Needed to Test